CD40 Ligand (D5J9Y) Rabbit mAb #15094
- WB
- IP
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 25-30 (membrane bound); 17 (soluble) |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:100 |
Storage
For a carrier free (BSA and azide free) version of this product see product #73222.
Protocol
Specificity / Sensitivity
CD40 Ligand (D5J9Y) Rabbit mAb recognizes endogenous levels of total membrane bound and soluble CD40 ligand protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human CD40 ligand protein.
Background
CD40 ligand (CD40L), also known as CD154, TRAP, and gp39, is the ligand for the TNF receptor family member CD40 (1-6). CD40L is expressed either as a soluble cytokine or as a homotrimeric transmembrane protein. CD40L primarily expressed on the surface of T-cells, but has also been reported in blood platelets, mast cells, basophils, NK cells, and B-cells. It plays an important role in stimulating B-cell cell proliferation and survival and promotes immunoglobulin class switching and secretion of IgE (7). Signals generated by CD40 vary depending on cell type and include activation of MAPK pathways as well as NF-κB (8-11). Mutations within the CD40L gene are associated with X-linked hyper-IgM syndrome characterized by high serum levels of IgM and decreased levels of other isotypes (12). The CD40L/CD40 pathway is an important area of interest in the study of cancer, vascular diseases, and inflammatory disorders (13-15).
- Noelle, R.J. et al. (1992) Proc Natl Acad Sci USA 89, 6550-4.
- Graf, D. et al. (1992) Eur J Immunol 22, 3191-4.
- Armitage, R.J. et al. (1992) Nature 357, 80-2.
- Hollenbaugh, D. et al. (1992) EMBO J 11, 4313-21.
- Gauchat, J.F. et al. (1993) FEBS Lett 315, 259-66.
- Castle, B.E. et al. (1993) J Immunol 151, 1777-88.
- Spriggs, M.K. et al. (1992) J Exp Med 176, 1543-50.
- Li, Y.Y. et al. (1996) J Immunol 157, 1440-7.
- Pearson, L.L. et al. (2001) Int Immunol 13, 273-83.
- Berberich, I. et al. (1996) EMBO J 15, 92-101.
- Aruffo, A. et al. (1993) Cell 72, 291-300.
- Berberich, I. et al. (1994) J Immunol 153, 4357-66.
- Korniluk, A. et al. (2014) Tumour Biol 35, 9447-57.
- Hassan, G.S. et al. (2012) Immunobiology 217, 521-32.
- Zhang, B. et al. (2013) Immunol Lett 153, 58-61.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.